JPMorgan Chase & Co. Analysts Give Fresenius Medical Care AG & Co. (Pref) (FME) a €95.60 Price Target

Fresenius Medical Care AG & Co. (Pref) (ETR:FME) has been given a €95.60 ($113.81) price target by research analysts at JPMorgan Chase & Co. in a research report issued on Wednesday. The firm currently has a “buy” rating on the stock. JPMorgan Chase & Co.’s price objective would suggest a potential upside of 4.00% from the company’s previous close.

A number of other brokerages have also weighed in on FME. Independent Research set a €90.00 ($107.14) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the company a “neutral” rating in a research note on Thursday, January 4th. UBS Group set a €87.00 ($103.57) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the company a “neutral” rating in a research note on Thursday, January 4th. Morgan Stanley set a €90.00 ($107.14) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the company a “neutral” rating in a research note on Monday, December 11th. Berenberg Bank set a €95.60 ($113.81) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a research note on Wednesday, December 6th. Finally, S&P Global set a €95.00 ($113.10) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a research note on Monday, November 6th. Ten investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Fresenius Medical Care AG & Co. (Pref) presently has a consensus rating of “Hold” and a consensus price target of €90.17 ($107.34).

Shares of Fresenius Medical Care AG & Co. (ETR:FME) opened at €91.92 ($109.43) on Wednesday. Fresenius Medical Care AG & Co. has a 12 month low of €73.87 ($87.94) and a 12 month high of €92.18 ($109.74). The firm has a market capitalization of $28,350.00 and a P/E ratio of 22.53.

ILLEGAL ACTIVITY WARNING: “JPMorgan Chase & Co. Analysts Give Fresenius Medical Care AG & Co. (Pref) (FME) a €95.60 Price Target” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2018/01/10/jpmorgan-chase-95-60-price-target.html.

Fresenius Medical Care AG & Co. (Pref) Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. (Pref) (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. (Pref) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. (Pref) and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit